Pushing Forward With Hematology Clinical and Research Efforts in Chaotic, Uncertain Times
June 2025
Andrew J. Cowan, MD
Dr. Cowan reflects on the current hematology research landscape.
Skip Nav Destination
Editor's Corner
Cyclophosphamide May Mitigate Movement, Neurocognitive Treatment-Emergent Adverse Events Following Cilta-Cel for R/R MM
June 2025
Cyclophosphamide may mitigate non-immune effector cell-associated neurotoxicity syndrome neurotoxicities, particularly movement and neurocognitive treatment-emergent adverse events, occurring in patients following treatment with the B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel (cilta-cel) for relapsed or refractory multiple myeloma (R/R MM).
Magrolimab Plus Azacitidine Did Not Improve Outcomes in TP53-Mutated AML
June 2025
The combination of CD47-targeting magrolimab plus azacitidine did not improve survival compared with physician’s choice of treatment in patients with TP53-mutated acute myeloid leukemia (AML), according to the results of the interim analysis of the ENHANCE-2 study.
Large Study Clarifies Risk of Thrombosis Associated With Protein S Deficiency
June 2025
Only a small percentage of individuals with low plasma levels of protein S have a mutation in the coding region of PROS1, the gene encoding a key circulating anti-coagulant factor. Additionally, a complete heterozygous protein S deficiency in which one copy of the PROS1 gene is nonfunctional is both rarer and more strongly linked to venous thrombosis than previously thought.
